celerihealth.com

What It Is

Celéri Health positions itself as a “pain and neuromodulation evidence infrastructure” company. It is not just a standalone registry system; rather, it connects point-of-care patient-reported outcomes, commercial registries, regulatory-grade real-world evidence, and de-identified data analytics. Its core users include MedTech and pharmaceutical companies, interventional pain physicians, payers, and clinical researchers.

Core Features and Integrations

The platform is organized into several layers: EaaS provides sponsors with a Commercial Insights Registry, Regulatory-Grade Evidence Cohort, and Traditional Prospective Study; PainIntel gives physicians practice-level registries, 30+ validated PRO instruments, and a real-time Pain Command Center; myPainIntel is the patient-facing iPhone app for PRO collection, pain visualization, interventions, and research consent; and PainRWD Science Cloud offers de-identified longitudinal real-world data for external controls, HEOR, payer evidence packages, and benchmarking. For integrations, the website mentions CRM enrollment, direct patient access via QR codes, and 8 EHR integrations at no additional cost, but it does not name the specific vendors.

Pricing and Compliance

Pricing is not publicly disclosed; prospective customers are primarily directed to Request Demo or speak with a strategy advisor. The official site emphasizes that EaaS is not a software license, but a combination of managed operations, regulatory infrastructure, and data science services. It also claims up to 85% lower costs than traditional CRO studies and an 8-week launch timeline. Compliance information is relatively detailed, with explicit references to 21 CFR Part 11, HIPAA, IRB-ready/IRB exempt workflows, eConsent, audit trails, and de-identified data.

Pros and Cons

Its strengths are deep vertical focus, a relatively complete path from commercial evidence to regulatory evidence, and an attempt to reduce site contracts, manual entry, and researcher workload. It should be especially useful for post-market evidence generation, payer communications, and medical affairs. Its weaknesses are that pricing, SLA, data residency, permission models, and API documentation are not disclosed. Its narrative is clearly centered on the U.S. FDA, HIPAA, and payer system, so suitability for China or other markets would need to be assessed case by case.

Who It’s For and Access from China

Celéri Health is better suited to medical device or pharmaceutical companies with pain, neuromodulation, or interventional therapy products that are already on the market or approaching launch, as well as U.S. pain clinics that want to turn routine care into structured evidence. Access from China and supported payment methods are not specified, so both should be considered unknown. For deployment in China, key areas to verify would include cross-border medical data handling, MLPS/PIPL compliance, Chinese localization, and local EHR integration. Comparable solutions include Medidata, Veeva, Castor EDC, REDCap, and Aetion.